Premature ovarian failure and tissue engineering

Ghahremani-Nasab, Maryam; Ghanbari, Elham; Jahanbani, Yalda; Mehdizadeh, Amir; Yousefi, Mehdi

doi:10.1002/jcp.29376

Cited by 68 publications

(33 citation statements)

References 93 publications

(196 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, the number and quality of functional oocytes in the ovary indicate the reproductive potential of females (Practice Committee of the American Society for Reproductive Medicine, 2015). Mature oocytes surrounded by GCs can react to relevant hormones and growth factors (Dewailly et al, 2016), such as FSH and bone morphogenetic proteins during folliculogenesis (Meduri et al, 2002;Dewailly et al, 2016).…”

Section: Ovarian Function and Characteristics Of Poimentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal Stem Cells in Premature Ovarian Insufficiency: Mechanisms and Prospects

Zhang

Tian

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Premature ovarian insufficiency (POI) is a complex endocrine disease that severely affects the physiological and reproductive functions of females. The current conventional clinical treatment methods for POI are characterized by several side effects, and most do not effectively restore the physiological functions of the ovaries. Transplantation of mesenchymal stem cells (MSCs) is a promising regenerative medicine approach, which has received significant attention in the management of POI with high efficacy. Associated pre-clinical and clinical trials are also proceeding orderly. However, the therapeutic mechanisms underlying the MSCs-based treatment are complex and have not been fully elucidated. In brief, proliferation, apoptosis, immunization, autophagy, oxidative stress, and fibrosis of ovarian cells are modulated through paracrine effects after migration of MSCs to the injured ovary. This review summarizes therapeutic mechanisms of MSCs-based treatments in POI and explores their therapeutic potential in clinical practice. Therefore, this review will provide a theoretical basis for further research and clinical application of MSCs in POI.

show abstract

Section: Ovarian Function and Characteristics Of Poimentioning

confidence: 99%

“…Therefore, combination of tissue engineering material and MSCs for transplantation represents a promising advanced approach for POI treatment with excellent therapeutic potential ( Ghahremani-Nasab et al, 2020 ). However, further studies should explore the inherent mechanism.…”

Section: New Approaches Based On Mscs ( Figure 3 )mentioning

confidence: 99%

Mesenchymal Stem Cells in Premature Ovarian Insufficiency: Mechanisms and Prospects

Zhang

Tian

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…The incidence of POF in women accounts for 1% [19], and CXT treatment is one of the causes of POF [20]. Therefore, treating ovarian degenerative changes and restoring ovarian function is the key to ensuring female reproductive health [21]. Although based on a large amount of data on the feasibility of stem cells to treat various degenerative diseases, however, due to the differences between animal models and the physical differences between model animals and humans, the therapeutic effects of stem cells are still controversial [22].…”

Section: Changes Of Gene Expression In the Ovaries Of Pof Mice Treatementioning

confidence: 99%

Effects of single transplantation and multiple transplantation of human umbilical cord mesenchymal stem cells on the recovery of ovarian function in the treatment of premature ovarian failure in mice

Guan²,

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundAt present, there is no effective treatment for premature ovarian failure (POF), and stem cell therapy is considered the most promising treatment. Human umbilical cord blood mesenchymal stem cells (hUC-MSCs) have shown good regenerative ability in a variety of diseases including POI, but the method and dosage of hUC-MSCs to treat POI are not clear. This study aims to explore the treatment options of hUC-MSCs for POF by comparing single injection and multiple injections of hUC-MSCs on the ovarian function repair of POF caused by chemotherapy drugs.MethodsFemale mice were injected intraperitoneally with 30 mg/kg of busulfan and 120 mg/kg of cyclophosphamide to induce POF. In the single hUC-MSCs injection group, 7 days after the mice were injected with cyclophosphamide and busulfan, hUC-MSCs were transplanted into these mice. In the multiple injection group, hUC-MSCs were transplanted 7 days, 14 days and 21 days after the mice were injected with cyclophosphamide and busulfan. We evaluated ovarian morphology, fertility, follicle stimulating hormone and estradiol concentration, and follicle count, evaluated POF model and cell transplantation. In addition, real-time PCR, immunohistochemistry, miRNA chip and mRNA chip are used to evaluate the effect of cell therapy.ResultsCompared with the POF group, the ovarian size and primordial follicle count in the hUC-MSC group were significantly improved, and the fertility was also significantly improved. Immunohistochemistry showed that compared with the POF group, the anti-Mullerian hormone and Ki-67 in the ovary of the hUC-MSC group increased significantly, and ovulation was significantly restored. Real-time PCR showed that the expression of follicle stimulating hormone receptor, inhibin and inhibin in the hUC-MSCs group was significantly restored compared with the POF group. The results of mRNA and miRNA chips also showed that hUC-MSC restored ovarian function at the gene level. long-term treatment effect shows that the multiple transplantation hUC-MSCs group is better than the single transplantation hUC-MSCs group. 60 days after the mice were injected with cyclophosphamide and busulfan, the organ coefficient of multiple transplantation of hUC-MSCs increased compared with the POF group, the number of primary follicles increased, and hormone secretion increased. ConclusionThe results show that multiple trasplantation of hUC-MSCs can promote the recovery of ovarian function in POF mice more than a single transplantation. This study provides a basis for the therapeutic dose and therapeutic effect of hUC-MSCs on POF.

show abstract

“…Several laboratories have used biomaterial scaffolds for in vitro cultivation to grow follicles outside the ovary or to create an artificial ovary [ 55 – 57 ]. To date, follicle-seeded scaffolds have been implanted by invasive methods such as intraovarian microinjection or kidney capsule transplantation [ 58 – 60 ].…”

Section: Introductionmentioning

confidence: 99%

Prevention of chemotherapy-induced premature ovarian insufficiency in mice by scaffold-based local delivery of human embryonic stem cell-derived mesenchymal progenitor cells

et al. 2021

View full text Add to dashboard Cite

Background Premature ovarian insufficiency (POI) is one of the most serious side effects of chemotherapy in young cancer survivors. It may not only reduce fecundity but also affect lifelong health. There is no standard therapy for preserving ovarian health after chemotherapy. Recently, administration of embryonic stem cell-derived mesenchymal progenitor cells (ESC-MPCs) has been considered a new therapeutic option for preventing POI. However, the previous method of directly injecting cells into the veins of patients exhibits low efficacy and safety. This study aimed to develop safe and effective local delivery methods for the prevention of POI using two types of bioinspired scaffolds. Methods Female mice received intraperitoneal cisplatin for 10 days. On day 11, human ESC-MPCs were delivered through systemic administration using intravenous injection or local administration using intradermal injection and intradermal transplantation with a PLGA/MH sponge or hyaluronic acid (HA) gel (GEL) type of scaffold. PBS was injected intravenously as a negative control. Ovarian function and fertility were evaluated 4 weeks after transplantation. Follicle development was observed using hematoxylin and eosin staining. The plasma levels of sex hormones were measured using ELISA. Expression levels of anti-Müllerian hormone (AMH) and ki-67 were detected using immunostaining, and the quality of oocytes and embryos was evaluated after in vitro fertilization. The estrous cycles were observed at 2 months after transplantation. Results The local administration of human ESC-MPCs using the bioinspired scaffold to the backs of mice effectively prolonged the cell survival rate in vivo. The HA GEL group exhibited the best recovered ovarian functions, including a significantly increased number of ovarian reserves, estrogen levels, and AMH levels and decreased apoptotic levels. Furthermore, the HA GEL group showed improved quality of oocytes and embryos and estrous cycle regularity. Conclusions HA GEL scaffolds can be used as new delivery platforms for ESC-MPC therapy, and this method may provide a novel option for the clinical treatment of chemotherapy-induced POI.

show abstract

Premature ovarian failure and tissue engineering

Cited by 68 publications

References 93 publications

Mesenchymal Stem Cells in Premature Ovarian Insufficiency: Mechanisms and Prospects

Mesenchymal Stem Cells in Premature Ovarian Insufficiency: Mechanisms and Prospects

Effects of single transplantation and multiple transplantation of human umbilical cord mesenchymal stem cells on the recovery of ovarian function in the treatment of premature ovarian failure in mice

Prevention of chemotherapy-induced premature ovarian insufficiency in mice by scaffold-based local delivery of human embryonic stem cell-derived mesenchymal progenitor cells

Contact Info

Product

Resources

About